Company / Cost of Revenue
Acadia Pharmaceuticals Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$89.0M
FY2025
5-year range
$10.2M / $89.0M
FY2021-FY2025
Trend
+8.7%
vs FY2024
Sector context
#44 of 85
Health Care
What the data says
At $89M, Acadia Pharmaceuticals's cost of revenue ranks #42 of 85 in the Health Care sector. Cost of Revenue has increased for 3 consecutive years, from $10M in FY2022 to $89M in FY2025.
Based on SEC 10-K filings.
$89M in FY2025 with a 5-year CAGR of +54.2%.
Increased from $42M to $89M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +106.1%
- 5-Year CAGR
- +54.2%
- 10-Year CAGR
- -
Sector benchmark
#42 of 85 in Health CareTop 48% of 85This company $89.0M Sector average $2.0B
▼
-95.5% below sector average
Key checks
Key Insights
- Acadia Pharmaceuticals's cost of revenue has grown for 3 consecutive years.
- 5-year CAGR of +54.2%, indicating consistent growth.
- In FY2025, cost of revenue increased 8.7% year-over-year.
- Ranks #44 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $89.0M | +8.7% |
| FY2024 | $81.8M | +96.6% |
| FY2023 | $41.6M | +309.6% |
| FY2022 | $10.2M | -46.9% |
| FY2021 | $19.1M | +87.5% |
| FY2020 | $10.2M | -10.0% |
| FY2019 | $11.3M | -8.3% |
| FY2018 | $12.4M | +36.4% |
| FY2017 | $9.1M | +195.2% |
| FY2016 | $3.1M | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026